🔗 Share this article

Given that the US proceeds with unprecedented changes to its vaccine schedules, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by questioning coronavirus shots during the global health crisis and has zeroed in on possible deaths following COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Agency leaders were set to announce sweeping changes to the pediatric vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, it is understood – a substantial departure that would put the US out of alignment with much of the world with no evidence for benefit. The planned update has been postponed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A Shift at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon dismantling already-approved immunizations at the FDA.

Høeg has often pushed for ending specific childhood vaccine recommendations in the US to become more in line with Denmark, a nation with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Questions Over Qualifications

Dr. Høeg has no apparent track record in drug development, approval processes or administrative roles, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a major agency. She is not an expert in industry regulation.”

Past heads of CBER would “understand legal statutes and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Clearly, she lacks the kind of background that former directors who headed the center have had.”

This division has an immense portfolio at the FDA, the former commissioner emphasized.

“Many people just focuses on the innovative therapies, but the generic program approves a multitude of generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and every single one must be looked after,” Woodcock noted. “The thing you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial leadership element to the role, which supervises in excess of 5,000 staff members. “It’s a enormous management job, if you perform it correctly,” she said.

Official Statement and Contentious Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson stated that the “questions are based on incorrect premises”.

“This background aligns with the responsibilities of her role,” the spokesperson said, noting the period Høeg spent advising the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a disputed rapid therapy clearance system that allegedly concerned her preceding directors. “How are these medications being selected for this expedited pathway? Who is making the choices?” Dr. Howard said. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards laxer regulations of all drugs, except for shots.”

Public Past Work on Vaccines

Regarding immunizations, Høeg has a clearer, if troubling, track record, some experts have noted. She authored a analysis using non-validated crowd-sourced reports to determine the frequency of heart inflammation following Covid immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the incoming government included revising regulations for new vaccines and ending “optional” vaccines, she stated after the election on a audio program. At the agency, Høeg has according to sources floated the idea of preventing young men from receiving COVID-19 vaccinations.

“She is an complete dogmatist who commences with her preconceived notions and works backwards to accommodate the data in a extremely disingenuous, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|